KR20210080418A - 신규한 용도 - Google Patents
신규한 용도 Download PDFInfo
- Publication number
- KR20210080418A KR20210080418A KR1020217013853A KR20217013853A KR20210080418A KR 20210080418 A KR20210080418 A KR 20210080418A KR 1020217013853 A KR1020217013853 A KR 1020217013853A KR 20217013853 A KR20217013853 A KR 20217013853A KR 20210080418 A KR20210080418 A KR 20210080418A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- pde1 inhibitor
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC1N(CC(CN)C(N2*)=O)C2=NC1=* Chemical compound CC1N(CC(CN)C(N2*)=O)C2=NC1=* 0.000 description 2
- BBIPVJCGIASXJB-PKTZIBPZSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Nc2ccccc2)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Nc2ccccc2)c11)C1=O BBIPVJCGIASXJB-PKTZIBPZSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748517P | 2018-10-21 | 2018-10-21 | |
| US62/748,517 | 2018-10-21 | ||
| PCT/US2019/057260 WO2020086481A1 (en) | 2018-10-21 | 2019-10-21 | Novel uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210080418A true KR20210080418A (ko) | 2021-06-30 |
Family
ID=70331921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217013853A Ceased KR20210080418A (ko) | 2018-10-21 | 2019-10-21 | 신규한 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12194042B2 (https=) |
| EP (1) | EP3866808A4 (https=) |
| JP (1) | JP7480135B2 (https=) |
| KR (1) | KR20210080418A (https=) |
| CN (1) | CN113194955A (https=) |
| AU (1) | AU2019364274C1 (https=) |
| BR (1) | BR112021007571A2 (https=) |
| CA (1) | CA3117148A1 (https=) |
| IL (1) | IL282396A (https=) |
| MX (1) | MX2021004531A (https=) |
| WO (1) | WO2020086481A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210614A1 (en) * | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP4413980A3 (en) | 2019-09-03 | 2024-10-30 | Intra-Cellular Therapies, Inc. | Novel compounds |
| MX2023008755A (es) * | 2021-01-27 | 2023-08-02 | Intra Cellular Therapies Inc | Cristales de sal. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2465893A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| RS52166B (sr) | 2007-05-11 | 2012-08-31 | Pfizer Inc. | Amino-heterociklična jedinjenja |
| KR20120012831A (ko) | 2007-12-06 | 2012-02-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| TW201206937A (en) * | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| US10918628B2 (en) * | 2016-10-11 | 2021-02-16 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Treatment of synucleinopathies |
-
2019
- 2019-10-21 US US17/287,478 patent/US12194042B2/en active Active
- 2019-10-21 KR KR1020217013853A patent/KR20210080418A/ko not_active Ceased
- 2019-10-21 JP JP2021521516A patent/JP7480135B2/ja active Active
- 2019-10-21 WO PCT/US2019/057260 patent/WO2020086481A1/en not_active Ceased
- 2019-10-21 MX MX2021004531A patent/MX2021004531A/es unknown
- 2019-10-21 CN CN201980084405.9A patent/CN113194955A/zh active Pending
- 2019-10-21 AU AU2019364274A patent/AU2019364274C1/en active Active
- 2019-10-21 BR BR112021007571-2A patent/BR112021007571A2/pt unknown
- 2019-10-21 EP EP19877180.0A patent/EP3866808A4/en active Pending
- 2019-10-21 CA CA3117148A patent/CA3117148A1/en active Pending
-
2021
- 2021-04-18 IL IL282396A patent/IL282396A/en unknown
-
2024
- 2024-12-03 US US18/967,095 patent/US20250090536A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12194042B2 (en) | 2025-01-14 |
| CN113194955A (zh) | 2021-07-30 |
| US20250090536A1 (en) | 2025-03-20 |
| AU2019364274A1 (en) | 2021-06-03 |
| EP3866808A4 (en) | 2023-04-12 |
| US20210379072A1 (en) | 2021-12-09 |
| BR112021007571A2 (pt) | 2021-07-27 |
| CA3117148A1 (en) | 2020-04-30 |
| AU2019364274C1 (en) | 2025-04-10 |
| EP3866808A1 (en) | 2021-08-25 |
| IL282396A (en) | 2021-06-30 |
| AU2019364274B2 (en) | 2024-10-17 |
| JP7480135B2 (ja) | 2024-05-09 |
| JP2022505471A (ja) | 2022-01-14 |
| WO2020086481A1 (en) | 2020-04-30 |
| MX2021004531A (es) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250090536A1 (en) | Uses | |
| EP2081431B1 (en) | Organic compounds | |
| JP6696904B2 (ja) | 製剤および医薬組成物 | |
| US20170231994A1 (en) | Organic compounds | |
| JP2016006042A (ja) | 有機化合物 | |
| JP2020023496A6 (ja) | 有機化合物 | |
| JP7749896B2 (ja) | 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター | |
| JP2002544232A (ja) | Ｎ−デスメチルゾピクロンの製造方法および使用方法 | |
| US20140271890A1 (en) | Controlled-release pharmaceutical composition | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| RU2836384C2 (ru) | Новые применения | |
| HK40057178A (en) | Novel uses | |
| CN101472571A (zh) | 使用毒蕈碱型受体m1拮抗剂治疗心理学病况 | |
| JP2025160326A (ja) | 処置方法 | |
| KR20090031908A (ko) | Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 | |
| Fischer | Parkinson’s disease and its existing therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |